AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29979888 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education
Number of subjects: 665
Study 29979888 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial factors
Number of subjects: 665
Study 29979888 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive nutrition education approaches
Number of subjects: 665
Study 26824595 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide administration for 10 days
Number of subjects: 161
Study 26824595 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning for 10 days
Number of subjects: 161
Study 26824595 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide administration and prone positioning for 10 days
Number of subjects: 161
Study 26824595 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control Group D)
Number of subjects: 161
Study 24806383 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (TLV) add-on group
Number of subjects: 100
Study 24806383 — intervention group
Group type: COMPARATOR
Intervention: Conventional diuretics group
Number of subjects: 100
Study 22032303 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupin protein + cellulose
Number of subjects: 175
Study 22032303 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea protein + cellulose
Number of subjects: 175
Study 22032303 — intervention group
Group type: COMPARATOR
Intervention: Casein + cellulose
Number of subjects: 175
Study 22032303 — intervention group
Group type: COMPARATOR
Intervention: Casein + oat fibre
Number of subjects: 175
Study 22032303 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea protein + oat fibre
Number of subjects: 175
Study 22032303 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein + apple pectin
Number of subjects: 175
Study 22032303 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea protein + apple pectin
Number of subjects: 175
Study 19852294 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐QBO
Number of subjects: 93
Study 19852294 — intervention group
Group type: EXPERIMENTAL
Intervention: F‐QBO
Number of subjects: 93
Study 19852294 — intervention group
Group type: COMPARATOR
Intervention: White Vaseline (Control)
Number of subjects: 93
Study 17515264 — intervention group
Group type: EXPERIMENTAL
Intervention: Kliniplot mattress
Number of subjects: 1729
Study 17515264 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital mattress
Number of subjects: 1729
Study 14742990 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus/Sirolimus (Group A)
Number of subjects: 0
Study 14742990 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus/Mycophenolate Mofetil (Group B)
Number of subjects: 0
Study 14742990 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (Neoral)/Sirolimus (Group C)
Number of subjects: 0
Study 12352037 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented parenteral nutrition with l‐alanyl‐l‐glutamine (0.3 g.kg.body weight per day)
Number of subjects: 144
Study 12352037 — intervention group
Group type: COMPARATOR
Intervention: Standard parenteral nutrition
Number of subjects: 144
Study 9839522 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Rectal Examination (DRE)
Number of subjects: 10523
Study 9839522 — intervention group
Group type: EXPERIMENTAL
Intervention: DRE in conjunction with serum PSA measurement and TRUS
Number of subjects: 10523
Study 9839522 — intervention group
Group type: EXPERIMENTAL
Intervention: DRE
Number of subjects: 10523
Study 7915442 — intervention group
Group type: EXPERIMENTAL
Intervention: cM‐T412 (chimeric CD4 monoclonal antibody)
Number of subjects: 11
Study 7915442 — intervention group
Group type: COMPARATOR
Intervention: Control group (antithymocyte globulin until cyclosporine in serum reached therapeutic levels)
Number of subjects: 11
Study 2655367 — intervention group
Group type: EXPERIMENTAL
Intervention: Modification of intravenous regional analgesia technique (removal of excess local anaesthetic solution)
Number of subjects: 0
Study 2655367 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of local anaesthetic agent removed from the isolated arm after 15 min
Number of subjects: 0
Study 2655367 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of excess local anaesthetic agent after 15 min
Number of subjects: 0
Study 1108754 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide 2 mg capsules, optimal daily dose ranged from two to seven capsules.
Number of subjects: 15
Study 1108754 — intervention group
Group type: COMPARATOR
Intervention: Loperamide 2 mg capsules (in double-blind placebo-controlled trial for ten days or until relapse).
Number of subjects: 15
Study 1108754 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide 2 mg capsules.
Number of subjects: 15
Study 31402400 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-out immersion in natural thermal mineral water (HINTMW) alone
Number of subjects: 1122
Study 31402400 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-out immersion in natural thermal mineral water (HINTMW) as an adjuvant therapy to medication
Number of subjects: 1122
Study 31402400 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-out immersion in natural thermal mineral water (HINTMW) combined with other interventions (natural convalescent factor therapy, psychotherapy, exercises, nutrition therapy, integrated care)
Number of subjects: 1122
Study 31402400 — intervention group
Group type: COMPARATOR
Intervention: Basic antihypertensive drugs
Number of subjects: 1122
Study 28722611 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferroquine + Artesunate (200 mg/day)
Number of subjects: 72
Study 28722611 — intervention group
Group type: COMPARATOR
Intervention: Amodiaquine (612 mg/day) + Artesunate (200 mg/day)
Number of subjects: 72
Study 25928545 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron-folic acid (IFA)
Number of subjects: 1258
Study 25928545 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly iron-folic acid (IFA)
Number of subjects: 1258
Study 25928545 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrients (MMN)
Number of subjects: 1258
Study 25928545 — intervention group
Group type: COMPARATOR
Intervention: Usual antenatal care (OS)
Number of subjects: 1258
Study 23816766 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium pretreatment
Number of subjects: 40
Study 23816766 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 40
Study 22292247 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic family planning/HIV integration model
Number of subjects: 274
Study 22292247 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced family planning/HIV integration model
Number of subjects: 274
Study 22292247 — intervention group
Group type: EXPERIMENTAL
Intervention: ART providers' family planning counseling
Number of subjects: 274
Study 18562447 — intervention group
Group type: EXPERIMENTAL
Intervention: Software application for managing hyperbilirubinaemia
Number of subjects: 15
Study 18562447 — intervention group
Group type: COMPARATOR
Intervention: Manual application of AAP guidelines
Number of subjects: 15
Study 18562447 — intervention group
Group type: EXPERIMENTAL
Intervention: Software application
Number of subjects: 15
Study 16924799 — intervention group
Group type: EXPERIMENTAL
Intervention: SCENAR therapy
Number of subjects: 103
Study 15180356 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine (10 mg)
Number of subjects: 30
Study 15180356 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine (120 mg)
Number of subjects: 30
Study 15180356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12903420 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanyl‐glutamine [0.5 g/(kg.d)]
Number of subjects: 30
Study 12903420 — intervention group
Group type: COMPARATOR
Intervention: Control group (isocaloric parenteral nutrition without glutamine)
Number of subjects: 30
Study 12903420 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 9350072 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin up to 2000 mg day-1
Number of subjects: 60
Study 9350072 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 60
Study 1440126 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam brush
Number of subjects: 29
Study 1440126 — intervention group
Group type: COMPARATOR
Intervention: Toothbrush
Number of subjects: 29
Study 3826915 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum phenobarbital measurements
Number of subjects: 70
Study 31698478 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (0.035 mg/kg)
Number of subjects: 6
Study 31698478 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 6
Study 29856175 — intervention group
Group type: EXPERIMENTAL
Intervention: Blueberry juice (500 mL/day for 14 days preoperatively)
Number of subjects: 26
Study 29856175 — intervention group
Group type: COMPARATOR
Intervention: Control group (no blueberry juice)
Number of subjects: 26
Study 26989182 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 351
Study 26989182 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 351
Study 26989182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 26586322 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week group psychotherapy intervention facilitated by a clinical psychologist
Number of subjects: 120
Study 26586322 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 22987106 — intervention group
Group type: EXPERIMENTAL
Intervention: JET group
Number of subjects: 54
Study 22987106 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 20682457 — intervention group
Group type: EXPERIMENTAL
Intervention: Practical group counseling (PGC) psychotherapy (n=14)
Number of subjects: 43
Study 20682457 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion HCl (n=14)
Number of subjects: 43
Study 20682457 — intervention group
Group type: COMPARATOR
Intervention: Matching pill placebo (n=15)
Number of subjects: 43
Study 18184396 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial weight loss programmes (specific diets not detailed)
Number of subjects: 0
Study 17199952 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone 200 mg daily (Group A)
Number of subjects: 76
Study 17199952 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone 100 mg daily (Group B)
Number of subjects: 76
Study 17199952 — intervention group
Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 76
Study 14618939 — intervention group
Group type: EXPERIMENTAL
Intervention: DEAE-Dextran at 2.5 g/day
Number of subjects: 202
Study 14618939 — intervention group
Group type: COMPARATOR
Intervention: Cholestyramine at 12 g/day
Number of subjects: 202
Study 10403579 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA enriched diet
Number of subjects: 6
Study 10403579 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 6
Study 7627695 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (0.5 g BID) added to diet and cholestyramine (8 g BID)
Number of subjects: 303
Study 7627695 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (0.5 g BID)
Number of subjects: 303
Study 2035782 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1% amethocaine hydrochloride
Number of subjects: 40
Study 2035782 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 40
Study 6119942 — intervention group
Group type: EXPERIMENTAL
Intervention: Azonutril 25
Number of subjects: 120
Study 6119942 — intervention group
Group type: EXPERIMENTAL
Intervention: Totamine Concentré Glucidic
Number of subjects: 120
Study 6119942 — intervention group
Group type: EXPERIMENTAL
Intervention: Vamine
Number of subjects: 120
Study 31608389 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive therapy (CT)
Number of subjects: 219
Study 31608389 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy (BT)
Number of subjects: 219
Study 31608389 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 219
Study 30089792 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of APL daily containing 970 mg of dihydromyricetin
Number of subjects: 80
Study 30089792 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 g of APL daily without dihydromyricetin)
Number of subjects: 80
Study 28610718 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea purpurea-derived alkylamides (Ec. extract) cream
Number of subjects: 0
Study 25972244 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen treatment
Number of subjects: 0
Study 25972244 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein expression of S6K1
Number of subjects: 0
Study 22517610 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg loading dose)
Number of subjects: 160
Study 22517610 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control Group)
Number of subjects: 160
Study 21435408 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV vaccine (RV144)
Number of subjects: 16402
Study 19380443 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan (350 or 300 mg/m² every 3 weeks)
Number of subjects: 491
Study 19380443 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX4 (infusional fluorouracil, leucovorin, and oxaliplatin)
Number of subjects: 491
Study 16283381 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (3 g before each chemotherapy cycle, followed by 1 g/day for 21 days)
Number of subjects: 20
Study 16283381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15518759 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus + mycophenolate mofetil (MMF) (FK group)
Number of subjects: 87
Study 15518759 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine + mycophenolate mofetil (MMF) (CSA group)
Number of subjects: 87
Study 12586132 — intervention group
Group type: EXPERIMENTAL
Intervention: Clivarin (4200 U once daily subcutaneous)
Number of subjects: 1200
Study 12586132 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH; 7500 anti-Xa U twice a day subcutaneous)
Number of subjects: 1200
Study 9825354 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - 0.625 mg/day oral conjugated estrogen for 4 weeks
Number of subjects: 10
Study 9825354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7667778 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-interferon preparations injected intramuscularly in a single weekly dose of 1.10(6) ‐ 1.5.10(6) IU for courses lasting from 1 to 6 months.
Number of subjects: 37
Study 7667778 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy for chronic persistent hepatitis B (CPHB).
Number of subjects: 37
Study 2709521 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous vein patch closure
Number of subjects: 140
Study 2709521 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene patch closure
Number of subjects: 140
Study 2709521 — intervention group
Group type: COMPARATOR
Intervention: Direct no‐patch closure
Number of subjects: 140
Study 1469 — intervention group
Group type: EXPERIMENTAL
Intervention: Community alternative treatment
Number of subjects: 0
Study 1469 — intervention group
Group type: COMPARATOR
Intervention: Psychiatric hospitalization
Number of subjects: 0
Study 7022244 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretransplantation splenectomy
Number of subjects: 50
Study 7022244 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATG) administration
Number of subjects: 50
Study 30818971 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-assisted activities with dogs
Number of subjects: 47
Study 30818971 — intervention group
Group type: COMPARATOR
Intervention: Novel toy and handler
Number of subjects: 47
Study 30241318 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic walking training
Number of subjects: 94
Study 30241318 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented group (SG)
Number of subjects: 94
Study 30241318 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 94
Study 26993636 — intervention group
Group type: EXPERIMENTAL
Intervention: PEER-DM intervention
Number of subjects: 42
Study 26993636 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 42
Study 25236367 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopic wedge resection and mechanical pleurodesis (WR+MP group)
Number of subjects: 289
Study 25236367 — intervention group
Group type: COMPARATOR
Intervention: Thoracoscopic wedge resection only (WR group)
Number of subjects: 289
Study 23170816 — intervention group
Group type: EXPERIMENTAL
Intervention: Online website refresher
Number of subjects: 0
Study 23170816 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mail refresher
Number of subjects: 0
Study 23170816 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging refresher
Number of subjects: 0
Study 23170816 — intervention group
Group type: COMPARATOR
Intervention: Mailed brochure (control)
Number of subjects: 0
Study 20615852 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture as the primary intervention
Number of subjects: 68
Study 20615852 — intervention group
Group type: EXPERIMENTAL
Intervention: Searching Chinese language databases
Number of subjects: 68
Study 20615852 — intervention group
Group type: EXPERIMENTAL
Intervention: Inconclusive findings regarding acupuncture effectiveness
Number of subjects: 68
Study 16837470 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 15 mg/day
Number of subjects: 1232
Study 16837470 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 50 mg/week
Number of subjects: 1232
Study 16837470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1232
Study 16837470 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg/day
Number of subjects: 1232
Study 15854187 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO)
Number of subjects: 1040
Study 15854187 — intervention group
Group type: EXPERIMENTAL
Intervention: PIO + MET
Number of subjects: 1040
Study 12352221 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 12
Study 12352221 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine-famciclovir
Number of subjects: 12
Study 12352221 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine-ganciclovir
Number of subjects: 12
Study 10549062 — intervention group
Group type: EXPERIMENTAL
Intervention: Vectrine (erdostein), one capsule b.i.d. for 21 days
Number of subjects: 170
Study 10549062 — intervention group
Group type: COMPARATOR
Intervention: Placebo, one similar capsule b.i.d. for 21 days
Number of subjects: 170
Study 7796625 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold crystalloid cardioplegia (St. Thomas Hospital solution) with hypothermic CPB
Number of subjects: 20
Study 7796625 — intervention group
Group type: COMPARATOR
Intervention: Warm blood cardioplegia with normothermic CPB
Number of subjects: 20
Study 2290779 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation training supported by temperature biofeedback for 10 weeks
Number of subjects: 0
Study 2290779 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 380466 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg propranolol
Number of subjects: 20
Study 380466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30785826 — intervention group
Group type: EXPERIMENTAL
Intervention: Four cycles of epirubicin (E) 90 mg/m2 and cyclophosphamide (C) 600 mg/m2 followed by four cycles of docetaxel (T) 100 mg/m2
Number of subjects: 2449
Study 30785826 — intervention group
Group type: COMPARATOR
Intervention: Six cycles of docetaxel (T) 75 mg/m2 and cyclophosphamide (C) 600 mg/m2
Number of subjects: 2449
Study 27986874 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethosuximide
Number of subjects: 208
Study 27986874 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid
Number of subjects: 208
Study 27986874 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine
Number of subjects: 208
Study 25824567 — intervention group
Group type: EXPERIMENTAL
Intervention: Florbetaben PET imaging
Number of subjects: 216
Study 24228862 — intervention group
Group type: EXPERIMENTAL
Intervention: Print-delivered basic intervention (PB)
Number of subjects: 439
Study 24228862 — intervention group
Group type: EXPERIMENTAL
Intervention: Print-delivered environmental intervention (PE)
Number of subjects: 439
Study 24228862 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based basic intervention (WB)
Number of subjects: 439
Study 24228862 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based environmental intervention (WE)
Number of subjects: 439
Study 24228862 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 439
Study 21864348 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucalyptus oil and lemon tea tree oil pediculicide (EO/LTTO)
Number of subjects: 92
Study 21864348 — intervention group
Group type: EXPERIMENTAL
Intervention: Melaleuca oil and lavender oil pediculicide (TTO/LO)
Number of subjects: 92
Study 21864348 — intervention group
Group type: EXPERIMENTAL
Intervention: Suffocation pediculicide
Number of subjects: 92
Study 19474053 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 30-60 mg/day
Number of subjects: 454
Study 19474053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 454
Study 17605565 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource-oriented stress management training (Zurich resource model training)
Number of subjects: 54
Study 17605565 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 54
Study 15318308 — intervention group
Group type: EXPERIMENTAL
Intervention: ml/kg RBW method
Number of subjects: 120
Study 15318308 — intervention group
Group type: EXPERIMENTAL
Intervention: ml/kg OBW method
Number of subjects: 120
Study 15318308 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSH method
Number of subjects: 120
Study 15318308 — intervention group
Group type: EXPERIMENTAL
Intervention: Retzlaff's method
Number of subjects: 120